Literature DB >> 21352660

Heliox and forward-leaning posture improve the efficacy of nebulized bronchodilator in acute asthma: a randomized trial.

Daniella C Brandão1, Murilo C Britto, Maira F Pessoa, Rafaela B de Sá, Luciana Alcoforado, Leonardo O Matos, Thayse N Silva, Armèle Dornelas de Andrade.   

Abstract

BACKGROUND: Heliox and forward-leaning posture (torso inclined forward at 50-60° with the elbows resting on the thighs) are adjuncts in the administration of nebulized bronchodilator to patients with acute asthma.
METHODS: We randomized 59 patients who presented to the emergency department in severe asthma crisis, into 4 treatment groups: nebulized bronchodilator + oxygen; nebulized bronchodilator + oxygen + forward-leaning posture; nebulized bronchodilator + heliox; and nebulized bronchodilator + heliox + forward-leaning posture. Before and after the bronchodilator treatments the subjects were seated with torso erect, breathing room air. Each subject received 2 doses, 20 min apart, of nebulized fenoterol (2.5 mg) plus ipratropium bromide (0.25 mg) in 3 mL of 0.9% saline, delivered with a semi-closed valved aerosol reservoir. The nebulizer was run with oxygen or 80:20 heliox. The post-treatment pulmonary function tests were performed 15 min after the second nebulization. The group's mean age was 35.1 ± 13.6 y, and there were 20 men and 39 women.
RESULTS: The oxygen + forward-leaning-posture group had a greater FEV(1) improvement than the oxygen group (59% vs 38%, P = .02). The heliox + forward-leaning-posture group had a greater FEV(1) improvement than the oxygen group (103% vs 38%, P = .001) and the heliox group (103% vs 42%, P = .03). The heliox group had greater reduction in respiratory rate than the oxygen group (P = .03). The heliox + forward-leaning-posture group had significantly greater peak expiratory flow improvement than any of the other groups.
CONCLUSIONS: Heliox plus forward-leaning posture during bronchodilator nebulization improves bronchodilator efficacy in patients with severe acute asthma. (ClinicalTrials.gov registration NCT00922350).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21352660     DOI: 10.4187/respcare.00963

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  6 in total

Review 1.  Pharmacotherapy of critical asthma syndrome: current and emerging therapies.

Authors:  T E Albertson; M Schivo; N Gidwani; N J Kenyon; M E Sutter; A L Chan; S Louie
Journal:  Clin Rev Allergy Immunol       Date:  2015-02       Impact factor: 8.667

Review 2.  The acute management of asthma.

Authors:  Timothy E Albertson; Mark E Sutter; Andrew L Chan
Journal:  Clin Rev Allergy Immunol       Date:  2015-02       Impact factor: 8.667

3.  Effect of heliox- and air-driven nebulized bronchodilator therapy on lung function in patients with asthma.

Authors:  Mohamad F El-Khatib; Ghassan Jamaleddine; Nadim Kanj; Salah Zeineddine; Hassan Chami; Imad Bou-Akl; Ahmad Husari; Marwan Alawieh; Pierre Bou-Khalil
Journal:  Lung       Date:  2014-03-19       Impact factor: 2.584

4.  Heliox-Driven Nebulization Has a Positive Effect on the Lung Function in Lipopolysaccharide-Induced Chronic Obstructive Pulmonary Disease Rat Model.

Authors:  Wenwen Wu; Xi Chen; Xiaohan Liu; Chengyuan Liu; Gendi Lu
Journal:  Med Sci Monit       Date:  2016-10-30

5.  Helium-oxygen mixture: clinical applicability in an intensive care unit.

Authors:  Milena Siciliano Nascimento; Érica Santos; Cristiane do Prado
Journal:  Einstein (Sao Paulo)       Date:  2018-11-08

6.  Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of Cochrane Reviews.

Authors:  Simon S Craig; Stuart R Dalziel; Colin Ve Powell; Andis Graudins; Franz E Babl; Carole Lunny
Journal:  Cochrane Database Syst Rev       Date:  2020-08-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.